4/A: C4 Therapeutics Chief Medical Officer Reports RSU Vesting and Tax Withholding

C4 Therapeutics, Inc.'s Chief Medical Officer, Leonard Reyno, reported the vesting of restricted stock units and associated tax withholding, resulting in a net increase in his beneficial ownership.

Summary

• Leonard Reyno, Chief Medical Officer of C4 Therapeutics, Inc. (CCCC), acquired 15,325 shares of common stock on July 10, 2025, due to the vesting of previously granted restricted stock units (RSUs).
• Concurrently, 7,382 shares were withheld by C4 Therapeutics, Inc. at a price of $1.99 per share to satisfy tax withholding obligations in connection with the RSU vesting.
• Following these transactions, Mr. Reyno's beneficial ownership of common stock stands at 166,382 shares.
• This filing is an amendment to a Form 4 originally filed on July 14, 2025, voluntarily submitted to report the acquisition of shares upon RSU vesting, which was initially disclosed in a Form 4 filed on July 12, 2023.

Sentiment

Score: 6

Explanation: The filing reports a routine vesting of restricted stock units for a key executive, which is a standard compensation event and not indicative of negative company performance. It reflects continued executive alignment with shareholder interests.

Positives

• The vesting of 15,325 restricted stock units for the Chief Medical Officer represents a standard compensation event, aligning executive interests with shareholder value.
• The transaction is a routine compensation mechanism and does not represent a sale of shares by the reporting person, indicating continued commitment to the company.

Negatives

• A total of 7,382 shares were withheld by the company to cover tax obligations, which reduces the net number of shares received by the Chief Medical Officer from the RSU vesting.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing details a routine insider transaction related to executive compensation, which is a common practice across all industries, including the biotechnology and pharmaceutical sectors. It reflects the standard mechanism for vesting equity awards for key personnel.

Related Party Transactions

• The vesting of restricted stock units and the subsequent withholding of shares for tax obligations represent a standard compensation-related transaction between C4 Therapeutics, Inc. and its Chief Medical Officer, Leonard Reyno.

Stakeholder Impact

• Shareholders: The transaction reflects the ongoing execution of executive compensation plans, which can lead to minor dilution but also aligns management's interests with long-term company performance.
• Employees: This is a standard form of equity compensation, common in the industry, and indicates the company's adherence to established compensation practices.

Key Dates

Keywords

C4 Therapeutics, CCCC, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Beneficial Ownership, Chief Medical Officer, Executive Compensation, Tax Withholding